Posted 16th October 2017 by Laura Berry
The past decade has witnessed huge advances in both scientific research and technological innovations within the drug discovery market. Here Dr James Willans, Chief Technology Officer of the not-for-profit organisation and educational charity, Lhasa Limited, discusses two significant areas that have the potential to further transform the industry over the coming years.
Posted 12th October 2017 by Jane Williams
Microbial ecology, our understanding of what determines the robustness and community dynamics of microbial consortia, and synthetic biology, the art of engineering microorganisms to perform particular physiological or metabolic functions, are rapidly becoming allies in the race to develop novel therapeutic strategies in the microbiome space.
Posted 11th October 2017 by Anna Gomez
An extensively used technique for evaluating the expression of tissue antigens and their behaviour is known as immunohistochemistry (IHC). In this technique, the primary antibody raised against the specific antigen and a secondary antibody against the primary one is used for detecting specific targets of clinical relevance. IHC has the greatest impact on diagnostic pathology compared to any other technique. Although modern methods of flow cytometry and molecular diagnosis have also contributed enormously, IHC still remains the most relevant solution for various pathological diagnostic problems.
Posted 9th October 2017 by Jane Williams
Presented at the 3rd Biologics and Biosimilars Congress, these 3 sets of slides are available to download and share with your colleagues.
Posted 6th October 2017 by Laura Berry
Since the minimal cell idea was proposed by Max Delbruck and his Phage School colleagues in the 1930s, biologists have sought to build a cell that encodes only the minimum set of genes necessary for life. Such a minimal cell could be used to investigate the first principles of cellular life.
Posted 4th October 2017 by Laura Berry
Interest in microbiota has reached all areas of human health and disease. As a result, the therapeutic potential of probiotics has expanded. 2013 saw a surge of investment into prebiotics and probiotics, coinciding with an increase in microbiome funding. In the last decade, investment has quadrupled.
Posted 29th September 2017 by Jane Williams
In 1869, Thomas Ashworth first observed circulating tumour cells (CTC) in the blood of a man with metastatic cancer using an optical microscope. He postulated that “cells identical with those of cancer itself being seen in the blood may tend to throw some light upon the mode of origin of multiple tumours existing in the same person”1.
Posted 27th September 2017 by Jane Williams
Discovering and developing new drugs is difficult. Very difficult indeed. The cost of developing a new medicine, when you factor in the costs of all those projects which fail before getting to market, is increasing and is Very Large Indeed so what can be done to get us out of this situation?